Law360, New York (September 21, 2009) -- Biotechnology company Biogen Idec Inc. commenced a tender offer Monday for all shares of Facet Biotech Corp., in a deal potentially worth $356 million.
In the proposal, Biogen Idec is offering Facet stockholders $14.50 per share in cash, and the offer requires a majority of outstanding shares to be sold to Biogen Idec....
